Barely Significant
← all excerpts

Olezarsen and Beyond: Emerging Targeted Treatments for Familial Chylomicronemia Syndrome and Related Triglyceride Disorders.

J Lipid Atheroscler · 2026 · PMC12875079 · PMID 41660532

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp <0.001actually significant
At 6 months, patients treated with 80 mg olezarsen experienced a mean triglyceride reduction of 43.5%, a highly significant improvement compared with placebo ( p <0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.